Tofacitinib benefit‐risk profile in chronic plaque psoriasis
Strober B, Gottlieb A, Kerkhof P, Puig L, Bachelez H, Chouela E, Imafuku S, Thaçi D, Tan H, Valdez H, Gupta P, Kaur M, Frajzyngier V, Wolk R. Tofacitinib benefit‐risk profile in chronic plaque psoriasis. British Journal Of Dermatology 2019, 180: e19-e19. DOI: 10.1111/bjd.17373.Peer-Reviewed Original ResearchBiologic treatmentSevere psoriasisPlaque psoriasisHigh doseChronic plaque psoriasisHerpes zoster infectionSevere plaque psoriasisAcceptable safety profileBenefit-risk profileNew oral drugsZoster infectionPatient yearsTofacitinib treatmentUlcerative colitisPatients' qualityRheumatoid arthritisSafety profileAppearance of skinClinical trialsOral drugsEffective treatmentSide effectsPsoriasisPatientsDrugs